CTLA4 and neoplasm: Preclinical models demonstrated complete tumor regression and sustained immunological memory in 40–60 % of anti-CTLA-4-treated mice, effects mechanistically linked to enhanced CD8+ effector T cell/Treg ratios (4.8 vs. 1.6 in controls) through FoxP3+ cell depletion [130].